

Skin Immune Mechanisms in Health and Disease

by Barbara S. Baker

Published by Garner Press (<http://www.garnerpress.com>)

Copyright © 2006 Garner Press

All rights reserved. This book, or parts thereof, may not be reproduced or redistributed in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the Publisher.

ISBN: 0-9551603-0-8

ISBN: 978-0-9551603-0-1 (From 1st January 2007)

 *Garner Press*

Contents

Preface	iii
List of Colour Plates	v

PART I: Immune Components of Skin

1. Skin Immune System: Cellular

1.1 T lymphocytes	1
1.1.1 T cell subpopulations	1
1.1.2 Intraepidermal and dermal T cells	2
1.1.3 TCR and Antigens/Superantigens	3
1.1.4 Restricted TCR V β families in skin	5
1.1.5 Restricted TCR δ families in skin	5
1.1.6 T lymphocyte homing to skin	5
1.1.6.1 Tethering and rolling	5
1.1.6.2 Firm adhesion	7
1.1.6.3 Transmigration/Extravasation	9
1.2 Antigen-presenting cells	9
1.2.1 Langerhans cells	9
1.2.1.1 Surface markers associated with antigen presentation	11
1.2.1.2 Immune receptors	11
1.2.1.3 Birbeck granules/Langerin	12
1.2.1.4 Proinflammatory cytokines	12
1.2.2 Langerhans cell precursors	12
1.2.3 Dermal dendritic cells	13
1.2.4 Macrophages	13
1.3 Keratinocytes	13
1.3.1 Cytokines and Cytokine receptors	13
1.3.1.1 Proinflammatory cytokines	14
1.3.1.2 Immunomodulatory cytokines	14
1.3.1.3 Suppressors of cytokine signalling	15
1.3.1.4 Growth factors	18
1.3.1.5 Colony stimulating factors	20
1.3.1.6 Interferons	20
1.3.1.7 Chemokines	20
1.3.2 Response to cytokines	21
1.3.2.1 Proliferation/Differentiation	21

1.3.2.2 Up-regulation of surface molecules	21
1.3.2.3 Cytokine/chemokine production	23
1.3.3 Integrins	23
1.3.4 Antigen/Superantigen Presentation	23
1.3.5 Apoptosis	24
1.4 Mast cells	25
1.4.1 Mast cell activation	25
1.4.2 Mediators and cytokines.....	25
1.5 Dermal endothelial cells	26
1.5.1. Leukocyte recruitment.....	26
1.5.2 Cytokines and cytokine receptors.....	27
1.5.2.1 Proinflammatory cytokines.....	29
1.5.2.2 Th-2 cytokines/growth factors.....	29
1.5.2.3 Colony stimulating factors	29
1.5.2.4 Chemokines.....	30
1.5.3 Antigen presentation.....	30
1.6 Fibroblasts	30
1.6.1 Cytokines, growth factors and chemokines.....	30
Summary	32
References.....	33

2. Skin Immune System: Humoral

2.1 Complement components.....	35
2.1.1 C3 and B.....	35
2.1.2 Complement regulatory proteins	37
2.2 Polyunsaturated fatty acid metabolites	39
2.2.1 Linoleic acid	39
2.2.2 Arachidonic acid.....	39
2.2.2.1 Prostaglandins	40
2.2.2.2 15-HETE and Leukotrienes.....	41
2.3 Secretory immunoglobulins	41
2.4 Cytokines and Chemokines.....	41
2.4.1 Interaction between keratinocytes and Langerhans cells	42
2.4.2 Interaction between keratinocytes and T cells.....	43
2.4.3 Interaction between keratinocytes and endothelial cells	43
2.4.4 Interaction between keratinocytes and fibroblasts.....	43
2.4.5 Leukocytes attracted by keratinocyte-derived chemokines	44
2.4.6 Cytokine inhibitors	44
2.5 Neuropeptides	45
2.5.1 Substance P.....	45

2.5.1.1. Cutaneous neuroinflammation..... 45

2.5.1.2 Modulation of immune cell function..... 45

2.5.2 Calcitonin gene-related peptide..... 48

2.5.2.1 Cutaneous neuroinflammation..... 48

2.5.2.2 Modulation of immune cell function..... 48

2.5.3 Neuropeptide Y..... 49

2.5.4.Somatostatin 49

2.5.5 VIP..... 49

2.5.6 PACAP..... 50

2.5.7 POMC-derived peptides 50

2.5.7.1 Modulation of immune cell function..... 51

2.5.7.2 Modulation of cutaneous cell function..... 51

2.6 Proteinase-activated receptors..... 51

2.6.1 PAR-1 52

2.6.2 PAR-2 52

2.7 Vanilloid receptor-1 53

Summary 54

References..... 55

PART II: Immune Responses in Skin

3. Skin Immune System: Innate Immunity

3.1 Alternative Complement Pathway 57

3.2 Components of Innate Immunity: PAMPs and PRRs..... 57

3.3 Phagocytic cells 58

3.4 Inflammatory Response 58

3.5 Pattern-Recognition Receptors in Normal Skin 59

3.5.1 Toll-like Receptors 60

3.5.1.1 TLR Structure and Signalling..... 60

3.5.1.2 TLR Ligands..... 60

3.5.1.3 TLR Expression by Peripheral Blood Leukocytes 64

3.5.1.4 TLR Expression by Resident Skin Cells 65

3.5.1.5 Responses by Skin Cells to TLR Activation 66

3.5.2 Nod proteins 68

3.5.3 Dectin-1 68

3.5.4 CD91..... 68

3.5.5 C-type Lectin Receptors..... 69

3.5.5.1 Macrophage C-type Lectin..... 69

3.5.5.2 Macrophage Mannose Receptor (CD206)..... 69

3.5.5.3 DEC-205 (CD205) 70

3.5.6 Integrins..... 70

3.6 Antimicrobial molecules in skin 70

3.6.1 Antimicrobial peptides..... 70

 3.6.1.1 Defensins 72

 3.6.1.2 Cathelicidins 73

 3.6.1.3 Dermcidin 73

 3.6.1.4 Adrenomedullin 73

3.6.2 Antimicrobial proteins 74

 3.6.2.1 Bactericidal permeability-increasing protein (BPI) 74

 3.6.2.2 Psoriasin (S100A7) and Calprotectin (S100A8/S100A9)..... 74

3.6.3 Antimicrobial molecules with enzyme/enzyme inhibitor activity 75

 3.6.3.1 RNase 7 75

 3.6.3.2 Antileukoprotease (ALP)..... 75

 3.6.3.3 Elafin (skin-derived serine protease inhibitor) 75

3.6.4 Antimicrobial Lipids..... 76

 3.6.4.1 Palmitoleic acid 76

 3.6.4.2 Sphingosine 76

3.7 NK cells 76

3.8 Interaction between Innate and Acquired Immunity..... 77

Summary 78

References..... 79

4. Acquired immune Responses: Immunological Hypersensitivity Reactions

4.1 Type I Hypersensitivity 83

4.1.1 Mechanism 83

 4.1.1.1 Initial exposure to allergen 83

 4.1.1.2 Subsequent exposure to allergen 85

 4.1.1.3 Late Reactions 87

4.1.2 IgE detection and measurement..... 87

 4.1.2.1 ELISA/RAST 87

 4.1.2.2 Skin prick test..... 87

4.1.3 Examples of type I hypersensitivities 88

 4.1.3.1 Anaphylaxis 88

 4.1.3.2 Food allergy..... 88

 4.1.3.3 Asthma and Hayfever 89

4.1.4 Treatment..... 89

 4.1.4.1 Modulation of the immune response to allergens 89

 4.1.4.2 Alleviation of clinical symptoms..... 89

4.2 Type II Hypersensitivity 90

4.2.1 Mechanism 90

 4.2.1.1 Phagocytosis/Antibody-dependent cellular cytotoxicity..... 90

4.2.1.2 Complement-mediated cytotoxicity	90
4.2.2 Examples of Type II hypersensitivity	92
4.2.2.1 Autoantibody-induced diseases	92
4.2.2.2 Natural antibody-induced transfusion reactions	92
4.2.2.3 Antibody-induced haemolytic reactions requiring previous sensitisation	93
4.2.2.4 Drug-induced blood cell destruction	93
4.2.3 Treatment	93
4.3 Type III Hypersensitivity	94
4.3.1 Mechanisms for phagocyte recruitment	94
4.3.1.1 Complement-dependent mechanisms	94
4.3.1.2 Complement-independent mechanisms	96
4.3.2 Phagocyte-induced tissue damage	96
4.3.3 Examples of type III hypersensitivity	97
4.3.3.1 Arthus reaction	98
4.3.3.2 Serum sickness	98
4.3.3.3 Farmer's lung/Bird fancier's lung	98
4.3.4 Treatment	99
4.3.4.1 Immunosuppressive drugs	99
4.3.4.2 Immunomodulation	99
4.4 Type IV Hypersensitivity	100
4.4.1 Generation of a cell-mediated immune response	100
4.4.1.1 Th-1 cytokine response	100
4.4.1.2 Th-2 cytokine response	100
4.4.2 Response to microorganisms	101
4.4.2.1 Microbial stimuli	101
4.4.2.2 Histology of reaction	102
4.4.2.3 Granuloma formation	102
4.4.3 Contact hypersensitivity	102
4.4.4 <i>In vivo</i> tests for type IV hypersensitivity	103
4.4.4.1 Detection of infection	103
4.4.4.2 Function of the immune system	103
4.4.4.3 Patch testing	104
4.4.5 <i>In vitro</i> tests for type IV hypersensitivity	105
4.4.5.1 Macrophage migration inhibition assay	105
4.4.5.2 Lymphocyte transformation assay	105
4.4.5.3 Cytokine assays	105
4.4.6 Treatment	106
4.4.7 Overlap of hypersensitivity types in an immune response	106
Summary	107
References	108
Further Reading	109

PART III: Immunological Mechanisms of Skin Disease

5. Antibody-Mediated Skin Diseases

5.1 Urticaria	111
5.1.1 Acute and chronic forms.....	111
5.1.2. Pathogenesis of urticaria.....	112
5.1.2.1 Causes of urticaria	112
5.1.2.2 Histology of skin lesions	112
5.1.2.3 Mast cell mediators	113
5.1.2.4 Kinins	114
5.1.2.5 Complement activation.....	115
5.1.2.6 Neuropeptides.....	116
5.1.2.7 Protease inhibitors	116
5.1.2.8 Other cell types.....	116
5.1.3 Types of urticaria	117
5.1.3.1 Acute idiopathic urticaria	117
5.1.3.2 Acute allergic urticaria	117
5.1.3.3 Pseudo-allergic (Non-immunological) urticaria.....	117
5.1.3.4 Contact urticaria	118
5.1.3.5 Physical urticarias.....	119
5.1.3.6 Chronic Idiopathic Urticaria.....	122
5.1.3.7 Hereditary Angioedema.....	123
5.1.3.8 Urticarial vasculitis.....	124
5.1.3.9 Urticaria Pigmentosa/Mastocytosis	124
5.1.4 Treatment.....	125
5.1.4.1. H ₁ -antihistamines	125
5.1.4.2 Other treatments	125
5.2 Pemphigus	126
5.2.1 Pemphigus vulgaris	126
5.2.1.1 Clinical features.....	126
5.2.1.2 Autoantibodies to desmoglein 3	126
5.2.1.3 Autoantibodies to desmoglein 1	129
5.2.1.4 Autoantibodies to other keratinocyte surface molecules.....	130
5.2.1.5 T cell autoreactivity to Dsg 3 in PV patients.....	130
5.2.1.6 MHC restriction/antigen specificity/TCR usage of autoreactive CD4 ⁺ T cells.....	130
5.2.1.7 T cell autoreactivity to Dsg 3 in normal individuals	131
5.2.2 Pemphigus foliaceus	131
5.2.2.1 Clinical features.....	131
5.2.2.2 Autoantibodies to desmoglein 1	133
5.2.2.3 T cell autoreactivity to Dsg 1 in PF patients	133

5.2.3 Paraneoplastic pemphigus	134
5.2.3.1 Clinical features.....	134
5.2.3.2 Autoantibodies to desmogleins and plakins	134
5.2.4 Treatment.....	135
5.3 Bullous pemphigoid	136
5.3.1 Clinical features.....	136
5.3.2 Autoantibodies to hemidesmosomal proteins.....	136
5.3.3 T cell autoreactivity to BP180 antigen	137
5.3.4 Treatment.....	138
Summary	139
References.....	140

6. Systemic Lupus Erythematosus

6.1 Clinical features	143
6.1.1 Joints and skin	143
6.1.2 Kidneys.....	144
6.1.3 Lungs/Heart	144
6.1.4 Central nervous system.....	145
6.1.5 Haematological changes.....	145
6.2 Aetiology	145
6.2.1 Genetic factors.....	145
6.2.1.1 Chromosomal linkage sites	146
6.2.1.2 Candidate genes.....	147
6.2.1.3 Mouse genetic models.....	152
6.2.2 Environmental	152
6.2.3 Hormonal factors.....	152
6.3 Immune Dysregulation.....	153
6.3.1 Defective T cell signalling.....	153
6.3.1.1 Increased protein tyrosine phosphorylation and Ca ²⁺ influx.....	153
6.3.1.2 TCR/CD3 ζ chain deficiency.....	154
6.3.1.3 Mechanisms involved in decreased transcription of CD3 ζ chain	155
6.3.1.4 Overexpression of FcR γ	156
6.3.2 Altered T cell function.....	157
6.3.2.1 Decreased proliferative/cytotoxic response.....	157
6.3.2.2 Decreased IL-2 production.....	157
6.3.2.3 Th-1 and Th-2 cytokines	158
6.3.2.4 Autoreactive helper T cells.....	158
6.3.2.5 Apoptosis	158
6.3.3 Defective B cell signalling	160
6.3.4 Autoantibodies.....	160

6.3.4.1 Nuclear antigens	160
6.3.4.2 Intracellular proteins.....	162
6.3.4.3 Phospholipids	162
6.3.5 Immune complexes.....	162
6.3.5.1 Normal clearance of immune complexes	162
6.3.5.2 Defective clearance of immune complexes in SLE.....	163
6.4 Model of Pathogenesis	163
6.5 Pathogenesis of skin lesions	164
6.6 Treatment	166
6.6.1 Anti-inflammatory and immunosuppressive drugs.....	166
6.6.2 New approaches to treatment	166
6.6.2.1 Immunosuppressant.....	167
6.6.2.2 Immunoablation.....	168
6.6.2.3 B cells as targets	168
6.6.2.4 Blocking of costimulatory molecules.....	168
6.6.2.5 Anti-IL-10/TNF- α therapy	168
6.6.2.6 Modulation of hormone system.....	169
6.6.2.7 Gene therapy.....	169
Summary	170
References.....	171

7. Allergic Contact Dermatitis

7.1 Clinical features	175
7.2 Genetics.....	176
7.2.1 Nickel-induced ACD	177
7.2.2 Paraphenylenediamine-induced ACD	178
7.3 Immunopathology of skin lesions	178
7.4 Sensitisation to allergens	179
7.4.1 Langerhans cell migration to lymph nodes	179
7.4.2 Regulation of Langerhans cell migration to lymph nodes.....	181
7.4.3 Antigen presentation within lymph nodes	181
7.5 Elicitation of ACD.....	182
7.5.1 Non-specific proinflammatory effects of haptens.....	182
7.5.2 Activation and recruitment of T cells to the skin.....	184
7.5.3 Amplification of T cell response.....	184
7.5.4 T cell-mediated keratinocyte damage.....	185
7.5.5 Immunoregulation of the contact sensitivity response	187
7.5.5.1 IL-10-producing Tr1 cells	187
7.5.5.2 CD4 ⁺ CD25 ⁺ regulatory T cells.....	188
7.6 Treatment	190

Summary 191
 References..... 192

8. Atopic dermatitis

8.1 Clinical features 195
8.2 Aetiology 195
 8.2.1 Genetics 196
 8.2.1.1 Genetic linkage..... 196
 8.2.1.2 Linkage sites shared by AD and psoriasis 196
 8.2.1.3 Candidate genes..... 198
 8.2.2 Environmental factors 204
 8.2.2.1 IgE-mediated allergy 204
 8.2.2.2 Food allergens 204
 8.2.2.3 Aeroallergens..... 205
 8.2.2.4 Secondary microbial infections 206
 8.2.2.5 The Hygiene Hypothesis 206
8.3 Innate immune system..... 209
 8.3.1 Innate immune factors 209
 8.3.1.1 Anti-microbial peptides 209
 8.3.1.2 IL-8 and induced nitric oxide synthetase 209
 8.3.2 TLR and CARD/Nod proteins 210
8.4 Immunological abnormalities 211
 8.4.1 T lymphocyte responses *in vitro* and *in vivo* 211
 8.4.2 Leukocyte function..... 212
 8.4.3 Dysregulation of IgE synthesis..... 213
 8.4.3.1 Increased total and allergen-specific IgE..... 213
 8.4.3.2 Impaired regulation of IgE production by cytokines..... 213
8.5 Defects of the epidermis 214
 8.5.1 Impairment of the skin barrier 214
 8.5.2 Keratinocyte defects 215
8.6 Immunopathology of AD..... 216
 8.6.1 Immunohistology of skin lesions..... 216
 8.6.2 Epidermal dendritic cells..... 216
 8.6.3 Model for pathogenesis of AD 216
 8.6.3.1 Antigen presentation..... 216
 8.6.3.2 Biphasic Th-2/Th-1 cytokine pattern 217
 8.6.3.3 Chemokines..... 219
 8.6.4 *S.aureus* and AD 219
 8.6.4.1 Colonisation of AD skin 219
 8.6.4.2 Staphylococcal superantigens..... 220

8.6.5 <i>Malassezia</i> and AD.....	222
8.6.6 Auto-allergens.....	222
8.7 Treatment	223
8.7.1 Prevention.....	223
8.7.2 Topical corticosteroids ± antibiotics.....	224
8.7.3 Topical tacrolimus and pimecrolimus.....	225
8.7.4 UV light.....	225
8.7.5 Systemic treatments.....	225
8.7.6 Biological response modifiers	226
Summary	227
References.....	228
Further Reading.....	232

9. Psoriasis

9.1 Clinical Features	233
9.2 Histology of skin lesions	233
9.3 Aetiology	234
9.3.1 Genetics	234
9.3.1.1 Evidence for a genetic basis	234
9.3.1.2 Genomic imprinting	234
9.3.1.3 HLA Associations.....	235
9.3.1.4 Genetic linkage/Positional candidate genes	236
9.3.1.5 Other candidate genes	242
9.3.1.6 Global gene expression in psoriatic skin.....	245
9.3.2 Environmental factors	245
9.3.2.1 Infections.....	245
9.3.2.2 Koebner reaction (trauma).....	246
9.3.2.3 Hormones/drugs	247
9.4 Innate immunity response.....	247
9.4.1 Altered TLR expression.....	247
9.4.2 Anti-microbial peptides/proteins	247
9.4.3 NK-T cells/ keratinocyte CD1d expression.....	248
9.4.4 Dendritic cell CD91 expression.....	248
9.5 Peripheral blood T lymphocyte abnormalities.....	248
9.5.1 T cell responses <i>in vitro</i> and <i>in vivo</i>	249
9.5.2 T cell homing.....	250
9.5.3 T cell cytokine profile.....	250
9.6 Keratinocyte defects	251
9.6.1 Response to IFN- γ	251
9.6.2 Chemokine profile	251

9.6.3 Resistance to apoptosis.....	252
9.7 Immunohistology of skin lesions	252
9.7.1 T cell subpopulations.....	252
9.7.2 Epidermal dendritic cells.....	253
9.7.3 Dermal dendritic cells.....	254
9.7.4 Endothelial cells	254
9.8 Role of T cells in psoriasis	255
9.8.1 Evidence that psoriasis is T cell-mediated	255
9.8.1.1 Immunosuppressive treatments	255
9.8.1.2 Psoriasis xenograft model in SCID mice	256
9.8.1.3 Bone-marrow transplantation.....	257
9.8.1.4 Stimulatory T cell supernatants.....	257
9.8.1.5 Low CD4+ T cells/HIV infection.....	257
9.8.2 T cell antigen specificity.....	258
9.8.2.1 T cell clonality.....	258
9.8.2.2 Microbial antigens.....	259
9.8.2.3 Autoantigens.....	259
9.8.3 Antigen presentation.....	260
9.9 Cytokines/Chemokines in skin lesions	260
9.9.1 Cytokines.....	261
9.9.1.1 T cell cytokines.....	261
9.9.1.2 Dendritic cell cytokines.....	262
9.9.1.3 Keratinocyte cytokines.....	262
9.9.2 Chemokines	263
9.10 Model for pathogenesis of psoriasis	264
9.11 Treatment.....	266
9.11.1 Established treatments for psoriasis	267
9.11.1.1 Steroid hormones.....	267
9.11.1.2 Immunosuppressive drugs	268
9.11.1.3 PUVA, Dithranol and Fumaric acid esters.....	268
9.11.2 Current and emerging biological therapies for psoriasis	269
9.11.2.1 Blocking T cell activation/costimulation.....	269
9.11.2.2 Inhibiting T cell proliferation	272
9.11.2.3 Cytokine blockade.....	272
9.11.2.4 Immune deviation.....	273
9.11.3 New systemic therapies for psoriasis.....	273
Summary	275
References.....	276
Further Reading.....	282

Glossary.....	283
Index.....	289
Colour Plates.....	303